Uric Acid - key ingredient in the recipe for cardiorenal metabolic syndrome
- PMID: 24454316
- PMCID: PMC3884201
- DOI: 10.1159/000355405
Uric Acid - key ingredient in the recipe for cardiorenal metabolic syndrome
Abstract
Elevated serum uric acid levels are a frequent finding in persons with obesity, hypertension, cardiovascular and kidney disease as well as in those with the cardiorenal metabolic syndrome (CRS). The increased consumption of a fructose-rich Western diet has contributed to the increasing incidence of the CRS, obesity and diabetes especially in industrialized populations. There is also increasing evidence that supports a causal role of high dietary fructose driving elevations in uric acid in association with the CRS. Animal and epidemiological studies support the notion that elevated serum uric acid levels play an important role in promoting insulin resistance and hypertension and suggest potential pathophysiological mechanisms that contribute to the development of the CRS and associated cardiovascular disease and chronic kidney disease. To this point, elevated serum levels of uric acid appear to contribute to impaired nitric oxide production/endothelial dysfunction, increased vascular stiffness, inappropriate activation of the renin-angiotensin-aldosterone system, enhanced oxidative stress, and maladaptive immune and inflammatory responses. These abnormalities, in turn, promote vascular, cardiac and renal fibrosis as well as associated functional abnormalities. Small clinical trials have suggested that uric acid-lowering therapies may be beneficial in such patients; however, a consensus on the treatment of asymptomatic hyperuricemia is lacking. Larger randomized controlled trials need to be performed in order to critically evaluate the beneficial effect of lowering serum uric acid in patients with the CRS and those with diabetes and/or hypertension.
Keywords: Cardiorenal metabolic syndrome; Chronic kidney disease; Fructose; Uric acid.
Figures
Similar articles
-
New insights into uric acid effects on the progression and prognosis of chronic kidney disease.Ren Fail. 2012;34(4):510-20. doi: 10.3109/0886022X.2011.653753. Epub 2012 Jan 20. Ren Fail. 2012. PMID: 22260409 Review.
-
Maladaptive immune and inflammatory pathways lead to cardiovascular insulin resistance.Metabolism. 2013 Nov;62(11):1543-52. doi: 10.1016/j.metabol.2013.07.001. Epub 2013 Aug 8. Metabolism. 2013. PMID: 23932846 Free PMC article. Review.
-
Uric Acid as a Cause of the Metabolic Syndrome.Contrib Nephrol. 2018;192:88-102. doi: 10.1159/000484283. Epub 2018 Jan 23. Contrib Nephrol. 2018. PMID: 29393133 Review.
-
Fructose and uric acid: is there a role in endothelial function?Curr Hypertens Rep. 2014 Jun;16(6):434. doi: 10.1007/s11906-014-0434-z. Curr Hypertens Rep. 2014. PMID: 24760443 Free PMC article. Review.
-
Uric acid: a starring role in the intricate scenario of metabolic syndrome with cardio-renal damage?Intern Emerg Med. 2012 Feb;7(1):5-8. doi: 10.1007/s11739-011-0642-3. Epub 2011 Aug 13. Intern Emerg Med. 2012. PMID: 21842242 Review.
Cited by
-
Incident gout and weight change patterns: a retrospective cohort study of US adults.Arthritis Res Ther. 2021 Mar 2;23(1):69. doi: 10.1186/s13075-021-02461-7. Arthritis Res Ther. 2021. PMID: 33653403 Free PMC article.
-
Hyperuricemia, Type 2 Diabetes Mellitus, and Hypertension: an Emerging Association.Curr Hypertens Rep. 2017 Sep;19(9):69. doi: 10.1007/s11906-017-0770-x. Curr Hypertens Rep. 2017. PMID: 28770533 Review.
-
Effects of topiroxostat in hyperuricemic patients with chronic kidney disease.Clin Exp Nephrol. 2018 Apr;22(2):337-345. doi: 10.1007/s10157-017-1452-3. Epub 2017 Jul 27. Clin Exp Nephrol. 2018. PMID: 28752287
-
Tumor lysis syndrome: A clinical review.World J Crit Care Med. 2015 May 4;4(2):130-8. doi: 10.5492/wjccm.v4.i2.130. eCollection 2015 May 4. World J Crit Care Med. 2015. PMID: 25938028 Free PMC article. Review.
-
Oral ethinylestradiol-levonorgestrel attenuates cardiac glycogen and triglyceride accumulation in high fructose female rats by suppressing pyruvate dehydrogenase kinase-4.Naunyn Schmiedebergs Arch Pharmacol. 2019 Jan;392(1):89-101. doi: 10.1007/s00210-018-1568-3. Epub 2018 Oct 1. Naunyn Schmiedebergs Arch Pharmacol. 2019. PMID: 30276420
References
-
- Flegal KM, Carroll MD, Ogden CL, Curtin LR. Prevalence and trends in obesity among US adults, 1999-2008. JAMA. 2010;303:235–241. - PubMed
Publication types
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources